Filana Therapeutics, Inc. FLNA
0.48 USD 0.00 (+0.00%)
At closeNov 11, 2026, 9:08 AM EST
0.50 +0.02 +3.67%
Pre-market · Nov 11, 9:08 AM ET
Day range unavailable
0.43 52-week range 3.45
- YTD
- -75.64%
- 1 year
- -84.08%
- Market cap
- 24.26M
- EPS (ttm)
- -0.87
- YTD return
- -75.64%
- 1-year return
- -84.08%
- Avg volume
- 2.04M
- Previous close
- 0.4823
- 52-week range
- 0.43 – 3.45
5D -0.0866 (-14.96%)
Financials — quick view
FLNA Revenue — quarterly 0
FLNA Net income — quarterly -10.73M
FLNA EPS — quarterly -0.22
News
Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Filana Therapeutics Q3 EPS $(0.22) Beats $(0.24) Estimate 
Filana Therapeutics Announces A Study Published By Yale Researchers Of New Preclinical Research On Simufilam Examined Simufilam's Impacts In Human Cell Line To Eliminate Tuberous Sclerosis Complex 2 Gene To Model Cellular Changes - 12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session - 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward 
FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy
Your note
Sign in to keep a note on FLNA — it syncs with the Stock Master app.